The c-Myc oncoprotein is a general transcription factor whose target genes dictate the c-Myc phenotype. One such target of c-Myc, 'onzin', is normally expressed at high levels in myeloid cells and is dramatically downregulated in response to c-Myc overexpression. We show here that short hairpin interfering RNA-mediated knockdown of endogenous onzin results in a reduced growth rate and a proapoptotic phenotype. In contrast, onzin overexpression in fibroblasts is associated with an increased growth rate, resistance to apoptotic stimuli, loss of the G2/M checkpoint, and tumorigenic conversion. Onzin-overexpressing cells fail to induce p53 in response to apoptotic stimuli and contain higher levels of the active, phosphorylated forms of Akt1 and, more strikingly, of Mdm2. Using yeast two-hybrid and coimmunoprecipitation assays, we show that onzin directly interacts with both proteins. Green fluorescent protein tagging also confirms directly that Akt1 and Mdm2 colocalize with onzin, although the precise subcellular distribution of each protein is dependent on its relative abundance. Collectively, our results identify onzin as a novel regulator of several p53-dependent aspects of the c-Myc phenotype via its dramatic effect on Mdm2. This is reminiscent of the c-Mycp19 ARF -| Mdm2 pathway and might function as a complementary arm to ensure the proper cellular response to oncogenic and/or apoptotic stimuli.
Introduction
C-MYC is among the most frequently deregulated proto-oncogenes in human cancers. The causes of its overexpression include gene amplification or translocation, seen in breast or prostate cancer and Burkitt's lymphoma, respectively. Overexpression may also result from the abnormal control of transcription factors that regulate the C-MYC gene, as occurs in a majority of colon cancers (Nesbit et al., 1999; Boxer and Dang, 2001) . Less frequently, mutations within the C-MYC gene itself lead to mRNA stabilization (Willis et al., 1997; Evans et al., 2003) .
Irrespective of the means by which control over c-Myc expression is lost, the outcome is deregulation of multiple c-Myc target genes, hundreds of which have now been identified (www.myc-cancer-gene.org). Recent work using whole genome chromatin immunoprecipitation has suggested that as much as 10-15% of the transcribed genome may be bound by c-Myc and subject to its transcriptional control (Fernandez et al., 2003; Li et al., 2003b) .
Thus far, most c-Myc target genes have been identified in established cells such as Rat1a fibroblasts. These are useful for evaluating several of c-Myc's wellknown functions, such as its ability to promote cell cycle progression, to accelerate apoptosis in response to various stimuli, and to impart anchorage-independent clonogenic growth and tumorigenic behavior. Individually, some targets can, when overexpressed, recapitulate a limited number of c-Myc phenotypes to varying degrees, most notably transformation and accelerated apoptosis (Wood et al., 2000; Prescott et al., 2001; Nikiforov et al., 2002; Yin et al., 2002) .
As an alternative for characterizing c-Myc targets, we have utilized the murine 32D myeloid cell line and identified >80 putative c-Myc target genes by transcriptional profiling (Nesbit et al., 2000) . Among those so far evaluated are MT-MC1 and CCL6 Yi et al., 2003) . The former is a positive c-Myc target whose overexpression recapitulates multiple c-Myc phenotypes. The latter, a member of the C-C chemokine family, is directly but oppositely regulated by c-Myc and L-Myc, and profoundly influences invasive and metastatic behavior.
We now report the characterization of a new c-Myc target gene, dubbed 'onzin', that is normally expressed at high levels in 32D cells and is markedly downregulated by c-Myc. We find that onzin, a small, highly conserved, cysteine-rich protein, can dramatically affect growth, cell cycle progression, and apoptosis in several different cell types. Inhibition of endogenous onzin expression results in a reduced growth rate and saturation density and an increased sensitivity to apoptotic stimuli. In contrast, the enforced expression of onzin in fibroblasts promotes growth, loss of cell cycle control, resistance to apoptosis, and tumorigenesis. The mechanism by which onzin imparts these phenotypes appears to involve its ability to activate the Akt-Mdm2 pathway, ultimately leading to an inability to upregulate p53.
Results

Onzin is highly conserved and its expression is tissue-restricted
We have previously shown that an expressed sequence tag (#697416, Nesbit et al., 2000) is markedly downregulated in 32D cells constitutively expressing high levels of c-Myc. The complete sequence of this EST, obtained in our laboratory, is 100% homologous to the reported sequence of 'onzin', which was independently sequenced and deposited in GenBank (Accession No. AAF76887) subsequent to the original sequencing of our clone.
A comparative database search revealed that murine and human onzin proteins are 82% identical ( Figure 1a ). Both are small (112 amino acids), with no obvious conserved functional domains. They do, however, contain a region of high cysteine content (11 of 33 residues), located between amino acids 28 and 61, that does not conform to consensus zinc-or RING-finger domains. However, within this region and elsewhere in the protein are several CXXC motifs. Such motifs have been previously described in members of the thioredoxin family, in DNA methyltransferase 1, CpG-binding protein, methyl-binding protein, and trithorax/ALL-1/ MLL (Ma et al., 1993; Bestor and Verdine, 1994; Hendrich and Bird, 1998; Voo et al., 2000) . CXXC motifs, which like zinc and RING fingers, can also coordinate zinc atoms, are involved in the catalysis of redox reactions by thiol : disulfide oxidoreductases and in the maintenance of protein conformation and homodimerization (Chivers et al., 1996 (Chivers et al., , 1997 Braspenning et al., 1998; Collet et al., 2003; Fomenko and Gladyshev, 2003) .
Northern analysis of established cell lines ( Figure 1b ) confirmed the downregulation of onzin transcripts in c-Myc-overexpressing 32D cells as described previously (Nesbit et al., 2000) . Friend erythroleukemia (F-MEL) cells also expressed onzin, although at much lower levels. None of the other cell lines expressed significant levels of onzin. In primary tissues, onzin was expressed at high levels in the intestine and spleen, and at somewhat lower levels in lung.
To confirm the potential regulatory relationship between onzin and c-Myc, 32D cells were deprived of interleukin-3 (IL-3), an obligate hematopoietic cytokine. We and others have previously shown that this results in Figure 1 Onzin is a highly conserved protein with marked tissue-restricted expression. (a) Amino-acid sequences of murine and human onzins (GenBank Acc. Nos. AF 26345 and NP_057703, respectively). Overall sequence identity was 82% and similarity was 87%. (b) Expression of onzin in various tissues and cell lines tissues. Total (5 mg) RNA from each of the indicated sources was probed with a 32 P-labeled onzin fragment containing the complete coding sequence. Note that 32D cells constitutively expressing c-Myc (32D-c-Myc) contained significantly lower levels of onzin transcripts, as has been described previously (Nesbit et al., 2000) . The lower panel shows the same blots rehybridized with a GAPDH probe as a control for RNA loading. (c) Onzin levels correlate inversely with those of endogenous c-Myc. Logarithmically growing 32D cells were deprived of IL-3 for the indicated periods of time. A blot containing 5 mg of RNA from each time point was then sequentially probed for c-Myc, onzin, and GAPDH Onzin, a c-Myc-repressed target K Rogulski et al an abrupt proliferative arrest, loss of c-Myc expression within 1-2 h, and eventual apoptotic demise, which first becomes detectable 12-16 h later (Nesbit et al., 1998) . As seen in Figure 1c , removal of IL-3 resulted in the expected rapid loss of c-Myc transcript expression and a parallel increase in onzin expression.
Onzin regulates the growth of 32D cells
The enforced overexpression of onzin in 32D cells resulted in no discernible phenotype (not shown). This was most likely attributable to the fact that these cells already expressed high levels of endogenous onzin (Figure 1b) . We therefore examined the consequences of 'knocking down' endogenous onzin in these cells by the stable expression of a short hairpin interfering RNA (shRNA). Two independent pools of 32D cells (designated 32D-sh1 and 32D-sh2), each stably transfected with an onzin shRNA expression vector, showed significant reductions in endogenous onzin transcripts compared to control cells, which were transfected with the parental vector containing a scrambled sequence ( Figure 2a ). All three cell lines expressed equivalent levels of c-Myc RNA. In transient transfection assays performed in 293 cells, the sh vectors were also capable of reducing epitope-tagged onzin protein levels by at least 80% (Figure 2b) .
Under standard conditions of in vitro propagation, both 32D-sh pools grew at significantly reduced rates and reached lower saturation densities than controls (Figure 2c ). In addition, 32D-sh cells were more prone to apoptotic death following IL-3 deprivation or to treatment with adriamycin ( Figure 2d and e). Collectively, these findings are consistent with the idea that endogenous onzin is a positive effector of both proliferation and survival in 32D cells.
As an additional control, we utilized an shRNAresistant form of onzin. This was created by introducing into the pSVL(MT)puro-onzin expression vector, third position mutations in the codons for Val 7 (GTT-GTG), Ile 8 (ATC-ATT), and Val 9 (GTG-GTT). Introduction of this vector into 293 cells cotransfected with an onzin shRNA expression vector demonstrated that transcripts for this mutant form of onzin, unlike those for the wild-type version, were completely resistant to shRNA 'knockdown' (Figure 2f ). Importantly, 32D-sh cells which expressed shRNA-resistant onzin (32D-sh þ sh R Onzin) showed a partial restoration of growth (Figure 2g ). In the experiments shown here, these cells reached a higher saturation density and survived longer than did control cells before undergoing apoptosis. These cells were also no longer hypersensitive to adriamycin exposure and, in fact, were even less sensitive than were control cells (Figure 2h ). These experiments confirmed that the proliferation and survival of 32D cells is highly dependent on levels of endogenous onzin. That the properties of cells reconstituted with the sh-resistant expression vector were not completely identical to those of control cells likely relates to differences in the control and/or levels of expression of endogenous versus vectorderived transcripts.
Onzin overexpression promotes growth, survival, and transformation
We next examined the consequences of onzin overexpression in two different primary, human fibroblast cell strains, WI-38 and IMR-90, and in the established Rat1a rat fibroblast line. None of these expressed detectable onzin transcripts as determined by Northern blotting (Figure 1b ; data not shown). Retroviral transduction was used to obtain pooled populations of both human strains (Landay et al., 2000) , whereas several clonal isolates of Rat1a cells were obtained following standard transfection with a nonretroviral onzin expression vector (Figure 3a) . In all three cases, control transfections were performed in parallel with vectors lacking onzin sequences. Studies on the growth rates of these cells demonstrated that onzin conferred a significant proliferative advantage to both human cell strains when propagated in standard medium containing 10% serum (Figure 3b) . Although the growth rates of Rat1a-onzin clones were indistinguishable from those of Rat1a-puro control cells under similar conditions, a significant growth advantage of the former cells was seen in medium containing 1% serum (Figure 3b ). Onzin, a c-Myc-repressed target K Rogulski et al
As both human cell strains showed high inherent resistance to serum deprivation and treatment with chemotherapeutic drugs such as adriamycin and VP-16 (not shown), it was not possible to determine the effects of onzin on their survival. Instead, we examined this in each of the above-described Rat1a-onzin and Rat1a-puro clones. As seen in Figure 4a and b, control Rat1a-puro cells were extremely sensitive to all three conditions, with >90% cell death occurring over a 2-7-day period. In marked contrast, each Rat1a-onzin clone not only demonstrated resistance to all three apoptotic stimuli, but actually continued to proliferate, albeit at reduced rates. Depending on the experiment, the clone, and the nature of the apoptotic insult, the total cell number increased by as much as 7-8-fold and ceased only upon achieving a densely confluent state. In other Figure 3 Onzin regulates the growth of primary human and established rat fibroblasts. (a) Onzin expression in WI-38 and IMR-90 human fibroblasts and in Rat1a fibroblasts. WI-38 and IMR-90 cells were infected with a recombinant pBABE-MN-IRES-GFP retrovirus encoding c-Myc epitope-tagged onzin. Control cells were infected with supernatants containing the encapsidated empty parental retroviral vector only. GFP-positive cells were purified by FACS, expanded and examined by Western blotting for onzin expression. Rat1a fibroblasts were stably transfected using Lipofectamine with the pSVLpuro(MT)onzin vector or the empty pSVLpuro(MT) vector. Individual puromycin-resistant clones were then expanded. Equivalent amounts of protein were then analysed for onzin expression. As a control for protein loading in all cell lines, the expression of actin was also assessed. (b) Onzin enhances the growth of primary and established cells. Cells from (a) were plated at a density of 2 Â 10 4 cells/well in 35-mm plates. WI-38 and IMR-90 cells were grown under standard conditions (10% serum), whereas Rat1a cells were grown in 1 or 10% serum. The total number of viable cells was then determined daily. Values are the average of three separate determinations 71 s.e. Figure 4 Rat1a-onzin cells are resistant to certain apoptotic stimuli. (a) Apoptosis in response to serum deprivation or exposure to VP-16 (125 nM) or adriamycin (10 nM). The indicated Rat1a-onzin or Rat1a-puro clones were plated at 10 5 cells/well, grown to 20-30% confluence, and then either deprived of serum or exposed to fresh medium containing VP-16 or adriamycin. Viable cell counts were then performed daily using trypan blue exclusion as described previously (Nesbit et al., 1998; Landay et al., 2000) . Ongoing apoptosis was documented by showing the presence of cells with a subdiploid DNA content and by the TUNEL assay as described previously (Mu et al., 2002 ; data not shown). (b) Phase-contrast micrographs of representative Rat1a clones 7 days after the removal of serum or 3 days after the addition of VP-16 or adriamycin. Note the confluent appearance of Rat1a-onzin cells under all three circumstances. (c) Apoptosis in response to c-Myc overexpression. Onzin-overexpressing or control Rat1a-MycER cells were grown to 50% confluency. On day 0, fresh medium lacking serum and either containing or not containing 250 nM OHT was added. Relative viable cell number was then determined daily as described above. (d) Phase-contrast micrographs of Rat1a-MycER cells 2 days after serum removal. (e) Rat1a-onzin cells are tumorigenic. Groups of six animals were inoculated subcutaneously with 2 Â 10 7 cells from the indicated Rat1a-onzin or Rat1a-puro clones and followed for the appearance of tumors. As a positive control, another group of animals were inoculated with Rat1a-c-Myc cells, which are highly tumorigenic . Tumor sizes were monitored weekly and are represented as the average size for the group 71 s.e. Note that, with prolonged observation, animals inoculated with control Rat1a-puro cells also developed tumors, although of significantly smaller size
experiments, we have shown that Rat1a-onzin cells could be maintained under these conditions for >6 weeks without a significant loss of viability or replating efficiency (not shown).
c-Myc deregulation promotes apoptosis in response to serum deprivation through mechanisms involving a variety of pathways (reviewed in Green, 1997; Prendergast, 1999; Juin et al., 2002) . In order to determine Onzin, a c-Myc-repressed target K Rogulski et al whether onzin could protect cells under these conditions, Rat1a cells expressing a Myc-estrogen receptor (Myc-ER) fusion protein (Yin et al., 2001a) were infected with onzin-encoding or control retroviruses and green fluorescent protein (GFP)-positive populations were isolated and expanded. The expression of onzin in the former pooled cells was confirmed by Western blotting and found to be comparable to that observed in the previously described human and Rat1a cells (not shown). These cells were then deprived of serum either in the absence or presence of 4-hydroxytamoxifen (OHT). As seen in Figure 4c and d, the activation of c-Myc by OHT resulted in a prompt and vigorous apoptosis in both cell populations. Thus, although onzin was capable of conferring protection against serum deprivation and chemotherapeutic agents, it was ineffective against c-Myc-mediated apoptosis. Similar results have been obtained in 32D cells which constitutively overexpress c-Myc (Nesbit et al., 2000) , and in the above-described IMR-90-onzin cells ( Figure 3 ) following infection with a c-Myc-encoding adenovirus (not shown). From these experiments, we conclude that, while onzin is strongly protective against certain forms of apoptotic stimuli, its effects are not global and can be overridden by c-Myc.
Unlike Rat1a cells which overexpress c-Myc or certain of its targets genes (Wood et al., 2000; Prescott et al., 2001; Nikiforov et al., 2002; Yin et al., 2002) , Rat1a-onzin cells were not clonogenic in soft agar (not shown). However, they were tumorigenic following subcutaneous inoculation into nude mice ( Figure 4e ). These tumors grew at the same rapid rate as those formed by Rat1a-c-Myc cells, and were of similar histologic appearance (not shown). Thus, like c-Myc, onzin functions in this context as an oncoprotein.
Onzin-overexpressing cells show loss of G2/M arrest and failure to upregulate p53 in response to apoptotic stimuli
In most primary and established cells, serum deprivation or exposure to chemotherapeutic drugs results in cell cycle arrest (Kaufmann, 1998; Nesbit et al., 1998; Chang et al., 1999; Mullan et al., 2001) . For example, we have shown that VP-16 and ADR treatment specifically leads to a cessation of 32D cell proliferation and to a G2/M block that precedes the onset of detectable apoptosis (Nesbit et al., 1998) . The continued survival and proliferation of Rat1a-onzin cells in the face of potent apoptotic stimuli (Figure 4a and b) therefore suggested that onzin overexpression might prevent or attenuate such a cell cycle arrest. We examined the cell cycle profiles of the above cell lines at various times following exposure to 125 nM VP-16. As seen in Figure 5a , Rat1a-puro and Rat1a-onzin cells showed identical cell cycle profiles prior to the addition of VP-16. Within 24 h of exposure to the drug, Rat1a-puro cells showed a G2/M arrest. This persisted at day 2, by which time a new population of subdiploid cells appeared, which coincided with the expected onset of apoptosis. In marked contrast, Rat1a-onzin cells failed to show a G2/M arrest and did not accumulate a detectable subdiploid population.
Instead, they demonstrated a gradual G0/G1 arrest that reflected their slowed growth and eventual attainment of confluency (Figure 4a and b). Similar results were seen when cells were treated with adriamycin and were reproduced with each of the other Rat1a-onzin clones (not shown). From these and previous experiments, we conclude that the enforced overexpression of onzin not only protects Rat1a cells from apoptosis, but also is able to overcome the permanent G2/M arrest that typically follows exposure to certain cytotoxic compounds.
The p53 tumor suppressor mediates cell cycle arrest in both G1 and G2/M and plays an important role in the initiation of apoptosis (Agarwal et al., 1995; Cross et al., 1995; Bunz et al., 1998; Oren, 2001; Weber and Zambetti, 2003) . Thus, we investigated whether alterations in p53 expression might explain the altered cell cycle profiles and apoptotic responses of Rat1a-onzin cells. As seen in Figure 5b , p53 was expressed at low levels in both Rat1a-puro and Rat1a-onzin cells during normal conditions of growth in 10% serum. Following the removal of serum or the addition of VP-16, p53 levels in the former cells increased to a variable extent as expected, whereas, in the latter cells, they paradoxically declined to undetectable levels. Thus, the survival and proliferation of Rat1a-onzin cells, and their inability to maintain a G2/M arrest, coincided with their failure to upregulate p53.
One of the key determinants of p53 abundance and activity is Mdm2. This RING finger E3 ubiquitin ligase suppresses the transcriptional activation of p53, enhances its nuclear-to-cytoplasmic shuttling, and promotes its ubiquitin-mediated degradation (Haupt et al., 1997; Ashcroft and Vousden, 1999; Freedman et al., 1999; Colman et al., 2000; Momand et al., 2000; Blattner et al., 2002; Li et al., 2003; O'Keefe et al., 2003 , and references therein). All of these activities are increased by Mdm2's phosphorylation on Ser 166 and are decreased by mutation of this residue (Mayo and Donner, 2001; Ashcroft et al., 2002) . Owing to its capacity to abrogate the antiproliferative effects of p53, Mdm2 overexpression is transforming (Ganguli et al., 2000; Moore et al., 2003; Steinman et al., 2004) . As many as one-third of soft tissue sarcomas show amplification and/or overexpression of Mdm2, as do a substantial fraction of breast and prostate cancers (Vousden, 2000) .
Given the central role of Mdm2 in inhibiting p53 function and promoting tumorigenic conversion, we determined the levels of total and phospho-Mdm2 (pSer166-Mdm2). In Rat1a-puro cells, total Mdm2 levels were equivalent to or only slightly higher than those in Rat1a-onzin cells, and either remained constant or declined somewhat in response to serum deprivation or VP-16 treatment, respectively. Phospho-Mdm2 levels in Rat1a-puro cells were either low or undetectable and remained so during the course of apoptosis. In contrast, a large increase in phospho-Mdm2 was observed in Rat1a-onzin cells following both serum deprivation and VP-16 treatment. Thus, the inability of Rat1a-onzin cells to upregulate p53 during apoptosis correlates with a dramatic increase in phospho-Mdm2. 5 cells/plate, grown to approximately 30% confluency, and exposed to 125 nM VP-16. Cells were then harvested at the indicated times, and their cell cycle profiles were determined by propidium iodide staining. Typical profiles from each group are presented. The percent of cells in each phase of the cell cycle was derived from 3-5 independent experiments, and is indicated as averages 71 s.e. (b) Western analyses of Rat1a-puro and Rat1a-onzin cells. Each of the indicated cell lines was grown to approximately 30% confluency. Following serum withdrawal or treatment with 125 nM VP-16 for the indicated times, cells were harvested, lysed and subjected to SDS-PAGE and Western blotting using antibodies directed against each of the indicated proteins. (c) Resistance of Rat1a-onzin cells to 6-TG. Rat1a-puro, Rat1a-onzin, and Rat1a-Akt1 cells were plated at 10 5 cells/plate in 100-mm dishes. The following day, the medium was removed and replaced with fresh medium containing 1 mM 6-TG. Cells were then incubated for an additional 5 days with a single change of 6-TG-containing medium before being fixed and stained with methylene blue to identify 6-TG-resistant colonies. (d) Onzin expression results in decreased levels of p53, p27, and p21. Lysates of logarithmically growing 32D cells expressing an onzin shRNA or a scrambled shRNA, and Rat1a control and onzin-expressing cells grown in 1% serum for 24 h were analysed by Western analysis, employing antibodies to the indicated proteins Onzin, a c-Myc-repressed target K Rogulski et al Among the kinases that phosphorylate Mdm2 at Ser 166 in response to growth factor stimuli is Akt1/ protein kinase B (Mayo and Donner, 2001; Ashcroft et al., 2002; Zhou and Hung, 2002) . Activation of Akt1, primarily by phosphorylation of Thr 308 and Ser 473, is often seen following growth factor stimulation and in certain neoplastic states (Chang et al., 2003; Paez and Sellers, 2003) . Furthermore, in a manner reminiscent of what we have observed for onzin, high levels of phosphorylated Akt1 inhibit apoptosis, impart resistance to chemotherapeutic drugs, override the G2/M checkpoint block in response to DNA damage, and are transforming (Testa and Bellacosa, 2001; Kandel et al., 2002; West et al., 2002; Chang et al., 2003, and references therein) .
Examination of the above Rat1a-puro and Rat1a-onzin lysates for total Akt1 showed relatively constant levels with little difference between the two cell lines. The only exception to this was seen in the case of VP-16-treated Rat1a-puro cells, where Akt1 levels declined during the latter stages of cell death but remained at basal levels in Rat1a-onzin cells. Levels of phospho-Akt (pSer473-Akt) also declined somewhat in Rat1a-puro cells in response to both apoptotic stimuli, whereas they increased in Rat1a-onzin cells, particularly those exposed to VP-16. These observations indicate that Rat1a-puro and Rat1a-onzin cells show differences, albeit small ones, in phospho-Akt1 levels that might potentially explain the more profound alterations in phospho-Mdm2 and p53.
Relatively small differences in activated Akt1 can have significant functional consequences. Among these are a striking resistance to 6-thioguanine (6-TG) similar to that seen in cells with defects in the mismatch repair mechanism (Kandel et al., 2002) . This occurs at >100 times the frequency, as does spontaneous 6-TG resistance, which generally involves mutations in the HGPRT gene. As seen in Figure 5c , no surviving colonies were observed among Rat1a-puro cells following a 5-day exposure to 1 mM 6-TG, whereas numerous 6-TG-resistant colonies arose from Rat1a-onzin cells. These developed at a frequency comparable to that seen in Rat1a cells constitutively expressing Akt1 (Rat1a-Akt1). The larger size of the former colonies may reflect a greater proliferative advantage conferred by onzin as demonstrated in Figure 4a . Therefore, onzin-overexpressing cells are similar to those which overexpress Akt in that both share comparably high intrinsic resistance to 6-TG.
Among the ways that p53 influences proliferation and apoptosis is via its regulation of important cyclindependent kinase inhibitors (CDKIs) such as p21 Waf1 and p27
Kip1 (El-Deiry et al., 1994; Yang et al., 2003; Philipp-Staheli et al., 2004) . We therefore examined the levels of these in two of the previously described cell lines (Figure 5d ). Compared to control cells, basal levels of p53, p21
Waf1
, and p27
Kip1 were higher in 32D-sh cells, consistent with their reduced proliferative capacity and enhanced susceptibility to apoptotic stimuli (Figure 2) . Conversely, in Rat1a-onzin cells grown in 1% serum, p53 and p27
Kip1 levels were both reduced. We were unable to detect p21 Waf1 in Rat1a-puro or Rat1a-onzin cells, most likely as a consequence of methylationmediated silencing of the p21
Waf1 promoter (Allan et al., 2000) . In other experiments we have shown that IMR90-onzin cells (Figure 3 ) also contain 2-3-fold lower levels of p21 and p27 than control cells (not shown). However, because p53 levels were extremely low in both cell types, we cannot say with certainty that there exists a direct correlation between the levels of p53 and these two CDKIs. Nonetheless, the existing results are consistent with the idea that the ability of onzin to regulate biological properties in various cell types is a consequence of its negative regulation of p53 and p53's downstream effectors, including p21
Waf1 and p27
Kip1
.
Onzin, Mdm2, and Akt show distinct and dynamic patterns of subcellular localization during growth and apoptosis
The finding that onzin overexpression was associated with alterations in the phosphorylation and activities of Akt and Mdm2 suggested that changes in the subcellular distribution of these proteins might be occurring as well.
To examine this in an unbiased manner, we created a series of fusions using enhanced blue (EBFP)-or enhanced yellow (EYFP)-shifted spectral analogs of GFP. Preliminary Western analyses of transiently transfected cells using an anti-GFP monoclonal antibody showed that each fusion was of the predicted size (not shown). We first examined the subcellular localization of EBFP-onzin and EYFP-Mdm2 during logarithmic growth and the early stages of apoptosis following serum deprivation or treatment with VP-16 ( Figure 6 , rows 1 and 2). In the former case, EBFP-onzin was distributed diffusely throughout the nucleus and cytoplasm of logphase Cos 7 cells, whereas, during apoptosis, particularly that induced by VP-16, more intense localization to the inner surface of the plasma membrane was seen. Under all conditions, EBFP-onzin was excluded from nucleoli. In log-phase cells, EYFP-Mdm2 was confined almost exclusively to the nucleus, although weak cytoplasmic fluorescence was seen in some cells. During apoptosis, the nuclear staining became speckled in appearance and a somewhat greater amount of cytoplasmic fluorescence was seen. As with EBFP-onzin, nucleolar localization of EYFP-Mdm2 was not observed.
In contrast to the above results, the coexpression of equimolar amounts of the two proteins resulted in a significant reduction of membrane and cytoplasmic localization of EBFP-onzin, and a more striking redistribution to the nucleus, where it strongly colocalized with EYFP-Mdm2 under all three conditions ( Figure 6, row 3) . When EBFP-onzin was coexpressed with a fourfold molar excess of non-GFP-tagged Mdm2 (pCMV-Mdm2), an even more striking relocalization of the former molecule was observed ( Figure 6, row 4) . Collectively, these results indicate that onzin typically occupies distinct and dynamic subcellular compartments, which are dependent on growth conditions and the relative abundance of Mdm2. Mdm2 promotes the redistribution of onzin from the membrane and cytoplasm into a much more prominent nuclear location where the two proteins colocalize.
Using the same strategy, we next examined the subcellular distribution of EBFP-Akt. As seen in Figure 7 (row 1), EBFP-Akt showed nuclear, cytoplasmic, and plasma membrane localization in untreated (control) cells, which was reminiscent of the pattern previously seen with onzin. Both serum deprivation and VP-16 treatment, however, resulted in a more pronounced localization of EBFP-Akt to the membrane and nucleus. Identical patterns were seen with EYFP-Akt (not shown). In general, less cytoplasmic localization of Akt was seen in the presence of these apoptotic stimuli than had been previously seen with onzin ( Figure 6) .
In control cells, coexpression of equimolar amounts of EYFP-Akt and EBFP-onzin resulted in colocalization of the proteins, which was quite similar to that seen with either one alone. Both maintained their colocalization following serum deprivation and VP-16 treatment, although a more impressive cytoplasmic localization was observed in most cells (row 2). When non-GFPtagged onzin was overexpressed relative to that of EBFP-Akt, an even more striking cytoplasmic Figure 6 Subcellular localization of onzin and Mdm2. EBFP-onzin or EYFP-Mdm2 were transiently expressed in Cos 7 cells either individually (rows 1 and 2) or at a 1 : 1 molar ratio (row 3). Immediately after transfection, cells were maintained in log phase growth (first column), were deprived of serum (second column), or were incubated in standard medium containing 125 nM VP-16 (third column). Cells were then fixed for visualization 16 h later. Typical images are shown. In row 4, pCMV-Mdm2, expressing a non-GFPtagged version of the protein, was cotransfected at a fourfold molar excess to EBFP-onzin Onzin, a c-Myc-repressed target K Rogulski et al redistribution of the latter protein was observed (row 3). From these experiments, we conclude that onzin and Akt also colocalize, and that onzin can influence the localization of Akt.
Onzin's interaction with Akt and Mdm2, and its biological activity require a short, cysteine-rich motif
The foregoing results demonstrating a dynamic colocalization of onzin and Mdm2 and onzin and Akt in mammalian cells strongly suggested that these proteins were physically interacting. We therefore utilized a yeast two-hybrid system to test this more directly. Full-length onzin was expressed as a fusion protein with the DNAbinding domain (BD) of the yeast Gal4 transcription factor. Several deletion mutants were also tested in order to map the region(s) of onzin necessary for any observed interactions (Figure 8a ). Full-length Mdm2 and Akt were expressed as fusions with the transactivation domain (AD) of Gal4. Pairs of BD and AD plasmids were then sequentially transformed into the AH109 yeast strain and selected on medium lacking either tryptophan or leucine, but containing histidine and adenine. Western blotting of lysates from each yeast strain demonstrated nearly equivalent levels of expression of the onzin deletion mutants (Figure 8b) .
We next evaluated each yeast strain to determine whether it could be propagated on medium lacking histidine and adenine, and if it could express b-galactosidase, as these properties would be indicative of protein-protein association (Langlands et al., 1997; Mu et al., 2002) . The latter measurement could also be used to quantify the relative strength of any such interactions (Langlands et al., 1997) . The results for Akt and Mdm2 were similar, but showed some differences. For example, based solely on the acquisition of His þ Ad prototrophy, only Akt was able to interact with full-length onzin (Figure 8a ). This association was weak, however, as judged by the relatively low level of b-galactosidase induction and by the inability of the two Figure 7 Subcellular localization of onzin and Akt1. Full-length GFP-tagged Akt was transiently expressed in Cos 7 cells as described above, either alone (row 1), at a 1 : 1 molar ratio with EBFP-onzin (row 2), or at a 1 : 4 molar ratio with pCMV-onzin (row 3). In row 2, the merged images are shown Onzin, a c-Myc-repressed target K Rogulski et al plasmids to confer His þ Ad prototrophy when selection was not initially performed on medium containing these nutrients (not shown). Although an interaction between onzin and Mdm2 was not detected based on the acquisition of His þ Ad prototrophy, a similarly low but significant level of b-galactosidase induction indicated a weak interaction nonetheless. Deletion of the C-terminal 72 amino acids of onzin (1-40, line 2) resulted in a more robust interaction with both proteins, suggesting the presence of a negative regulatory domain in the deleted region. Deletion of the N-terminal 19 and C-terminal 52 amino acids from onzin (20-60, line 3) further strengthened the interaction with Akt, suggesting the presence of an additional negative regulatory domain at this end of the molecule. Additional deletions, including one that removed 10 amino acids of the cysteine-rich domain (lines 4 and 5), totally abrogated the interaction of onzin with both Akt and Mdm2, and were thus consistent with this region being necessary and sufficient for the interactions.
To obtain independent confirmation of the above interactions, we performed coimmunoprecipitation experiments. Strains expressing full-length onzin or the mutants depicted in Figure 8a were grown to equivalent densities, pelleted and lysed in immunoprecipitation buffer. Following the addition of antibodies directed against Akt1 or Mdm2, immunoprecipitates were resolved by SDS-PAGE and subjected to Western transfer. The blots were then probed with a monoclonal anti-c-myc antibody, which recognized the epitope present in each of the onzin proteins. As seen in Figure 8c , full-length onzin along with the (1-40) and (20-60) deletion mutants were detected in both Akt1 and Mdm2 immunoprecipitates, whereas the remaining proteins were not. These results were consistent with the yeast two-hybrid results shown in Figure 8a . (Figure 1 ) that was removed to make the del(28-38) construct. Yeast strains expressing the indicated plasmids were initially selected on plates lacking tryptophan and leucine, but containing histidine and adenine. The ability to confer histidine and adenine prototrophy was then assessed by streaking pooled colonies onto plates lacking these nutrients. Relative b-galactosidase levels were determined on equivalent amounts of cell lysates obtained from yeast grown in liquid cultures containing histidine and adenine. The results shown here are the average of triplicate determinations, with standard errors in all cases being o5% (not shown). (b) Western analyses of each of the Gal4-onzin fusion proteins depicted in (a). Equivalent amounts of yeast lysates (50 mg) were resolved by SDS-PAGE and the presence of each fusion protein was detected with an antibody directed against a c-Myc epitope, which is encoded by the pGBKT7 vector and resides between the Gal4 and onzin moieties of each fusion protein. (c) Coimmunoprecipitation of the full-length and truncated forms of onzin and Akt1 or Mdm2 in yeast. Total protein lysates were prepared from yeast cotransformed with pGAD24-Akt1 or pGAD24-Mdm2 and pGBKT7 expressing either the wild-type or deleted forms of onzin depicted in (a). Lysates were incubated with antibodies against Akt1 or Mdm2, followed by precipitation with protein A agarose. Immunoprecipitates were evaluated by Western blotting using the 9E10 monoclonal antibody which recognizes the c-Myc epitope tag of the onzin proteins Onzin, a c-Myc-repressed target K Rogulski et al
Behavior of onzin mutants in Rat1a cells
The foregoing experiments suggested an important role for the cysteine-rich region residing between amino acids 28 and 38 in onzin. Therefore, we generated several Rat1a clones that expressed the del(28-38) mutant (Figure 9a ) and compared their behaviors to control Rat1a1 cells or those which overexpressed full-length onzin (Figure 9b) . In contrast to these latter cells, none of these clones was protected from apoptosis in response to either serum starvation or VP-16 treatment. Thus, we conclude that the cysteine-rich region encoded by amino acids 28-38 of onzin is critical for its antiapoptotic activity.
In order to confirm directly the interactions between onzin and Akt and Mdm2 in mammalian cells, we performed coimmunoprecipitation experiments from three of the above Rat1a cell lines. Total protein lysates Figure 9 The cysteine-rich region of onzin is important for its biological activity. (a) Western analysis of onzin-del(28-38)-expressiing Rat1a clones. Single clones of Rat1a cells, transfected with pSVLpuro(MT)onzin-del(28-38) were analysed for expression of the protein by Western blotting. Controls included Rat1a-onzin, Clone 21 and Rat1-puro, Clone 11 (see Figure 3) . (b) The Rat1a-del(28-38) clones and control clones shown in (a) were examined for their apoptotic response following serum deprivation or treatment with 125 nM VP-16, as described in the legend to Figure 4 . Note that each Rat1a-del(28-38) clone behaved like Rat1a-puro control cells in response to both stimuli. (c) Coimmunoprecipitation of onzin and Akt (top panel) or onzin and Mdm2 (bottom panel) from Rat1a cells. Total protein lysates from the indicated cell lines were incubated with antibodies against Akt (top panel) or Mdm2 (bottom panel) ( þ ) or with a control antibody (À), followed by precipitation with protein A-agarose beads. Immunoprecipitates were then analysed by Western blotting and probed with a monoclonal antibody against the Myc epitope tag of onzin. Note that full-length onzin was successfully precipitated in both cases, whereas onzin-del(28-32) was not precipitated. (d) fails to localize to the nucleus. EBFP-onzin-del(28-38) was expressed in logarithmically growing Cos 7 cells (panel 1) or in cells that were deprived of serum (panel 2) or treated with VP-16 (panel 3) as described previously Onzin, a c-Myc-repressed target K Rogulski et al were immunoprecipitated using polyclonal antibodies directed against total Akt or Mdm2, or with a control antibody. The precipitates were then resolved by SDS-PAGE, blotted and probed with a monoclonal antibody directed against the c-Myc epitope of the onzin moiety. As seen in Figure 9c , wild-type onzin was immunoprecipitated in association with both Akt and Mdm2, whereas onzin del(28-38) was not. These results were therefore confirmatory of those performed in yeast (Figure 8) , and provided direct evidence for an association between onzin and Akt1 and Mdm2. Finally, we asked whether the loss of biological activity of onzin del(28-38), and its inability to interact with Akt1 or Mdm2, might be due to a misguided subcellular localization. We therefore created an EBFP fusion protein and showed that a protein of the predicted size was produced (not shown). When this was expressed in Cos 7 cells, however, it failed to localize to the nucleus or nuclear membrane irrespective of conditions ( Figure 9d ).
Discussion
We have demonstrated here that onzin, a negative c-Myc target with tissue-restricted expression, regulates the proliferative and apoptotic responses of several established and primary cell types. For example, in 32D myeloid cells, where it is normally expressed at high levels, onzin's enforced downregulation by shRNA is accompanied by a markedly slower growth rate, a reduced saturation density, and an enhanced susceptibility to apoptotic insults. Conversely, in primary human or established rat fibroblasts, which contain little, if any, onzin, its overexpression can promote proliferation, survival, and tumorigenic conversion. Given the large number of genes and the diverse cellular processes governed by c-Myc (Fernandez et al., 2003; Li et al., 2003b) , the finding that a single target could exert such global control over some of the most prominent c-Myc functions argues that the minimal repertoire of c-Myc-regulated genes needed to recapitulate the c-Myc phenotype may either be quite small and/or that certain genes, such as onzin, play disproportionately important roles.
Other than a functionally important cysteine-rich domain with multiple CXXC motifs, onzin contains no obvious structural motifs to suggest a potential function. However, because of its effect on proliferation, survival, and oncogenesis, and because its overexpression abrogates the normal p53 response and cell cycle arrest following apoptotic stimuli, we investigated onzin's relationship to Akt1 and Mdm2. Collectively, our results support a model in which onzin regulates the activities of both these proteins (Figure 10 ). In addition to the biological evidence cited above, support for this model is based on our findings that onzin promotes the phosphorylation of Mdm2 and, to a lesser extent, of Akt1, redirects the subcellular distribution of Akt1, and physically associates with both proteins in yeast and mammalian cells. Our finding that a mutant form of onzin, incapable of interacting with Akt1 or Mdm2, is biologically inactive and excluded from the plasma membrane and nucleus, is also compatible with this model.
To some degree, c-Myc's promotion of apoptosis is dependent on its indirect upregulation of p53 (Wagner et al., 1994 , Prendergast, 1999 . The reliance on this protective cellular pathway is underscored by the finding that tumors arising as a result of c-Myc overexpression frequently contain inactivating mutations in p19 ARF , Mdm2, or p53 (Eischen et al., 1999) . p19 ARF , which is encoded by an alternate reading frame of the INK 4a locus , is upregulated in response to cMyc overexpression (Zindy et al., 1998; Jacobs et al., 1999) . p19 ARF sequesters Mdm2 in the nucleolus, thus preventing it from mediating ubiquitin-mediated degradation of p53 and its nuclear-to-cytoplasmic shuttling Weber et al., 1999) . The importance of the p19 ARF -Mdm2-p53 pathway is ARF and the downregulation of Akt1 by c-Myc have been described previously (Eischen et al., 1999; Guo et al., 2000) . p19
ARF inhibits Mdm2 function by sequestering it within the nucleolus and by blocking its ubiquitin-mediated degradation of p53 Eischen et al., 1999) . Akt1 stabilizes Mdm2, promotes its nuclear localization, and enhances its ubiquitin-mediated degradation of p53 (Ashcroft et al., 2002; Blattner et al., 2002; Ogawara et al., 2002; O'Keefe et al., 2003) . Via a third pathway described here, onzin, a negative c-Myc target, promotes the activation of Mdm2 and Akt1. This appears to be the result of increased phosphorylation of both proteins, particularly the former. Additional activation may result from the physical associations between onzin and Akt1, and onzin and Mdm2, with ensuing changes in the subcellular trafficking of the proteins. In addition, the fact that a dominantnegative form of onzin did not significantly affect its antiapoptotic effects or the ability to grow in the presence of 6-TG (not shown) suggests that onzin may also activate Mdm2 via Akt-independent mechanisms (dashed line). p53-independent pathways activated by c-Myc deregulation may explain the inability of onzin to protect against c-Myc-induced apoptosis (Figure 4c and d) Onzin, a c-Myc-repressed target K Rogulski et al further underscored by the finding that Hdm2, the human ortholog of Mdm2, is often amplified in soft tissue sarcomas and breast and prostate cancers (Vousden, 2000) . Our observation that onzin colocalizes and interacts with Mdm2 and promotes its phosphorylation-mediated activation suggests that onzin may represent an alternate arm of the pathway by which c-Myc conveys proapoptotic signals via p53. The inability of onzin to protect against apoptosis induced by c-Myc deregulation (Figure 4c and d) underscores the additional p53-independent proapoptotic pathways through which c-Myc functions (Prendergast, 1999) , as well as the specificity of onzin for functions associated with the Akt1-Mdm2-p53 axis.
In addition to the pathways discussed above, c-Myc also affects the level and activity of p53 by an independent pathway involving the downregulation of Akt1 (Guo et al., 2000) . Akt1-dependent phosphorylation of Mdm2, particularly on Ser 166, has been previously demonstrated to be an important means by which Akt1 can indirectly downregulate p53 and thus promote survival, drug resistance, cell cycle progression, and oncogenic transformation (Datta et al., 1999; Page et al., 2000; Ashcroft et al., 2002; Kandel et al., 2002; Ogawara et al., 2002; Paez and Sellers, 2003) . Through its association with Akt1, particularly at the plasma membrane, onzin may promote a more efficient interaction with membrane-bound serine/threonine kinases such as PDK1 and PDK2, which phosphorylate Akt1 at Thr 308 and Ser 473, respectively (Peterson and Schreiber, 1999; Vanhaesebroeck and Alessi, 2000) . As the onzin-Akt1 association at the plasma membrane and nucleus is particularly evident during serum deprivation or other apoptotic stimuli (Figure 7) , it may well be independent of Akt's ability to also localize to the membrane in response to growth factors. This latter property involves the interaction of Akt's aminoterminal pleckstrin homology domain with the phospholipid PtdIns(3,4,5)P3, which is generated by activated PI-3 kinase (Comer and Parent, 2002) .
The phosphorylation of Mdm2 by Akt1 is believed to occur primarily in the nucleus (Mayo and Donner, 2002) . We suggest that the ability of onzin to interact with both Akt1 and Mdm2 may be an important means by which they are brought into physical proximity and the phosphorylation of the latter protein is enhanced. The subsequent fate and function of Mdm2 is likely to be depend on its level and may involve monoubiquitination of p53 and its nuclear-to-cytoplasmic shuttling, or p53 polyubiquitination and nuclear degradation (Mayo and Donner, 2001; Li et al., 2003a) . On the other hand, we have found that the expression of a dominantnegative form of Akt1 (Burgering and Coffer, 1995) in Rat1a-onzin cells does not reverse the effects of onzin on proliferation or survival. Moreover, these cells continue to show high levels of Mdm2 phosphorylation and an inability to upregulate p53 (not shown). This suggests that alternate, Akt1-independent, pathways leading to Mdm2 activation may exist and/or that the level of this inhibitory protein was insufficient to affect the action of endogenous Akt1 on Mdm2.
As a result of their interactions with onzin, Akt1 and Mdm2 may also affect the activities and locations of other proteins which function via p53-independent pathways Testa and Bellacosa, 2001; Ganguli and Wasylyk, 2003) . For example, the ability of activated Akt1 to override G2/M arrest is largely p53-independent (Kandel et al., 2002) . Similarly, Akt1-mediated phosphorylation and inhibition of the forkhead transcription factor lead to cell survival and proliferation via pathways that appear to be p53-independent and, in some cases, involve the indirect inhibition of the p27 Kip1 cdk inhibitor Liang and Slingerland, 2003) . Mdm2 has also been reported to have several p53-independent modes of action as well (Vargas et al., 2003) . Irrespective of its mode of activation and the means by which it ultimately exerts its antiapoptotic effect, it seems highly likely that Mdm2, via its down regulation of p53, represents the major downstream onzin effector.
Materials and methods
Plasmids and recombinant DNA techniques
A murine onzin cDNA (GenBank Accession No. AF263458) containing the entire coding region was obtained from Incyte Pharmaceuticals (St Louis, MO, USA). The coding region was amplified by the polymerase chain reaction (PCR) using the following primers: forward: 5 0 -CGC GTC GAC AAG ATG GCT CAG GCA CCA AC-3 0 ; reverse: 5 0 -CGC GTC GAC GAC GAA AGC GTT CAT GGC TCT CCT C-3 0 , where italicized bases indicate 'GC clamps' and SalI sites to facilitate cloning. The reverse primer encoded the penultimate codon, but not the termination codon. Following SalI digestion, the product was purified by agarose gel electrophoresis and ligated into XhoI-digested pSVL-(MT)puro Yi et al., 2003) , resulting in the in-frame fusion of the N-terminus of onzin with a c-Myc epitope tag. The orientation of the resulting clone was confirmed by DNA sequencing. For some experiments, a CMV-based expression vector containing a similarly amplified onzin cDNA fused at its 5 0 -end to a FLAG epitope in the pCMV2-FLAG vector (Eastman Kodak, Inc., Rochester, NY, USA) was used. For expression of onzin in primary fibroblasts, the Myc epitope-tagged onzin cDNA was amplified from the pSVL-(MT)puro vector and cloned into the pMN-IRES-GFP retroviral vector (Landay et al., 2000) . For stable expression of Akt in Rat1a cells, the complete coding region of Akt was fused with the c-Myc epitope tag in the pSVL-(MT)puro vector. Expression of the properly sized, epitopetagged protein was confirmed by Western blotting (not shown).
A dominant-negative form of Akt1 (K179A) (Burgering and Coffer, 1995) under the control of an SV40 early promoter was a generous gift from Dr Paul Coffer (University of Utrecht).
An onzin shRNA expression vector was constructed in pSilencer2.1U6-neo (Ambion, Austin, TX, USA). Nucleotides 95-114 of murine onzin were used as the targeting sequence for the vector, which was otherwise constructed according to the directions of the supplier. To facilitate directional cloning, the complete 70-bp-long double-stranded insert contained a BamHI overhang at its 5 0 -end, and a 3 0 -HindIII overhang. The entire insert was sequenced in recombinant clones using the U6 forward primer recommended by the supplier.
A vector encoding shRNA-resistant onzin mRNA was constructed from the pSVL-(MT)puro-onzin expression vector described above using a Stratagene QuickChange mutagenesis kit (Stratagene, LaJolla, CA, USA). Briefly, the codons encoding Val 7 (GTG), Ile 8 (ATC), and Val 9 (GTG) were altered to GTT, ATT, and GTT, respectively. GFP expression vectors encoding CMV immediate early promoter-driven EYFP and EBFP variants have been described previously (Yin et al., 2001b) , and are based on the pEGFP-C1 parental expression vector structure (Clontech, Inc., San Diego, CA, USA). Fusions with onzin were created by cloning the PCR-amplified onzin coding sequence and its termination codon, into the SalI site of the polylinker. Murine Akt1 and Mdm2 cDNAs were generous gifts from Dr Nissim Hay (College of Medicine, Univ. of Illinois, Chicago, IL, USA) and Dr Christine Blattner (Institute of Genetics and Toxicology, Karlsruhe, Germany), respectively. As with onzin, both coding sequences were amplified by PCR and were cloned into their respective EYFP and EBFP vectors so as to be in inframe with the GFP coding sequence. In each case, the orientation and reading frame were confirmed by DNA sequencing. Expression of a fusion protein of the predicted size was confirmed by Western blotting of Cos 7 cell lysates using an anti-GFP monoclonal antibody (Clontech).
Yeast two-hybrid plasmids were derived from the starting plasmids pGBKT7 (Clontech) and pGAD424 (Langlands et al., 1997; Mu et al., 2002) . The former consists of the yeast Gal4 DNA BD under the control of the ADH promoter. PGBKT7-onzin was constructed by cloning the full-length onzin cDNA or truncated versions thereof, so that their 5 0 -ends were in-frame with the BD and a c-Myc epitope tag encoded by the vector. An internal deletion of onzin (del(28-38)) was obtained using a Quickchange kit. pGAD424-Akt1 and pGAD424-Mdm2 were constructed by cloning the fulllength PCR-amplified coding region of each molecule, including its termination codon, into the SalI site of the vector. Transformations and quantitative b-galactosidase assays were performed as described previously (Langlands et al., 1997; Yin et al., 2003) .
Northern analyses
Northern blots were performed essentially as described Yi et al., 2003) with 5 mg of total RNA per lane, blotted to Nytran membranes (Schleicher & Schuell, Keene, NH, USA), and hybridized in UltraHyb solution (Ambion, Austin, TX, USA). Probes consisted of cDNAs corresponding to the full-length coding regions of the indicated transcripts.
Cell culture and transfections
Rat1a, Cos 7 and Phoenix-A cells, and the primary human fibroblast cell strains IMR-90 and WI-38, were maintained in Dulbecco's modified minimal essential medium (D-MEM) supplemented with 10% fetal calf serum, 2 mM glutamine, 100 U/ml penicillin G, and 100 mg/ml streptomycin (all from GIBCO-BRL, Grand Island, NY, USA). 32D clone 3 myeloid cells were maintained as described previously (Nesbit et al., 1998) in RPMI medium with all of the above additional supplements plus 10% IL-3-conditioned medium obtained from WEHI-3B cells.
Transfections of adherent cells were performed in 60 mm plates with Lipofectamine (Invitrogen) using 1-2 mg of plasmid DNA. To obtain stable transfectants, Rat1a cells were trypsinized 2 days after transient transfection and replated in fresh medium containing 1 mg/ml puromycin (Sigma, St Louis, MO, USA) or 500 mg/ml G418 (GIBCO-BRL). Individual puromycin-or G418-resistant clones were picked 12-15 days later and expanded for further analysis.
Retroviral vectors were packaged in the Phoenix-A cell line. Fibroblasts were infected overnight with retroviral supernatants in the presence of 8 mg/ml polybrene. At 3-4 days after infection, GFP-positive cells were purified by cell sorting, expanded as described previously (Landay et al., 2000) , and utilized for all subsequent studies.
32D cells stably expressing onzin shRNA were obtained by electroporating 2 Â 10 7 cells with 5 mg of AflIII-linearized vector (Nesbit et al., 1998) . The resultant G418-resistant clones were pooled for further study.
Cell viability studies were performed with a Vi-Cell viability analyzer (Becton-Coulter Instruments, Maimi, FL, USA) according to the directions of the supplier. At least 1000 events were recorded for each time point.
For assays of anchorage-independent clonogenic growth, cells were cultured in soft agar as described previously .
For colony formation assays, cell monolayers were washed three times with PBS, fixed in methanol, and stained with methanol-2% methylene blue for 10 min, followed by exhaustive washing in distilled water.
For GFP expression studies, Cos 7 cells were plated onto glass coverslips in 60 mm dishes. The following day, cells were transfected for 4 h with GFP-fusion expression plasmids (1 mg/ plate) using Lipofectamine. Monolayers were then washed free of the DNA-Lipofectamine mixture and were either maintained under log phase growth for the next 16 h or were incubated in the absence of serum or in the presence of 125 nM VP-16 (Etoposide, Sigma). At the end of this period, coverslips were washed three times in PBS and fixed in PBS-2% paraformaldehyde. GFP fluorescence was observed with an Olympus Provis Visual Optical System using Magnafire Digital Imaging software (Olympus America, Melville, NY, USA) outfitted with a triple pass filter (Chroma Technology Corp., Rockingham, VT, USA).
SDS-PAGE and Western blotting
Cell monolayers were washed twice with PBS, trypsinized, and then washed twice again in PBS. Total cell pellets were lysed in 1 Â SDS-PAGE lysis buffer and boiled as described previously (Nesbit et al., 1998) , and total protein was quantitated using the BCA kit (Pierce, Rockford, IL, USA). b-Mercaptoethanol was then added to a final concentration of 5%. Depending upon the experiment, 25-50 mg of total cellular protein was then boiled for 10 min and resolved on a 10% or 12% polyacrylamide gel. Electroblotting was performed under semidry conditions onto a PVDF membrane (Millipore, Inc., Bedford, NY, USA). All blots were blocked for at least 1 h in PBS-0.25%Tween-20 (PBS-T) containing 5% nonfat dry milk, and all antibody incubations were performed in the same mixture. Antibodies were used at concentrations recommended by the suppliers and were incubated with the blots at room temperature for 2-4 h or overnight at 41C with constant agitation. Following extensive washing in PBS-T at room temperature, blots were again incubated with a 1 : 2000 dilution of horseradish-peroxidase-labeled secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and the blots were developed using an ECL kit (Amersham, Boston MA, USA) using the conditions recommended by the supplier. Antibodies included anti-p53 (#Ab-1, Calbiochem, San Diego, CA, USA), anti-Mdm2 (#sc-965, Santa Cruz), anti-phosphoMdm2 (pSer166) (#3521, Cell Signalling Technology, Bedford, MA, USA), anti-Akt1 (#5G3, Cell Signaling Technology), anti-phospho-Akt1 (pSer473) (#9271, Cell Signaling Technology), anti-c-Myc 9E10 (#sc-40, Santa Cruz), and anti-actin (#sc-8432, Santa Cruz).
Onzin, a c-Myc-repressed target K Rogulski et al Coimmunoprecipitation experiments from Rat1a fibroblasts were performed as described previously (Mu et al., 2002) . Briefly, confluent Rat1a cell monolayers were washed three times in PBS, collected by scraping, washed an additional three times in PBS and resuspended in 0.32 M sucrose, 150 mM NaCl, 10 mM Tris-HCl pH 7.5, 5 mM MgCl 2 and 1% Triton X-100 (Sigma) containing a protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA). After 10 min on ice, the cells were disrupted by a 30-s pulse with the microtip of a Branson sonifer at a setting of 7 and then cleared by centrifugation at 10 000 g for 5 min. In all, 500 mg (for the detection of Akt1) or 1 mg (for Mdm2) of the cleared lysate was then incubated for 2 h at 41C with 10 ml of control rabbit serum, followed by 50 ml of Protein A-agarose (Affigel; BioRad, Hercules, CA, USA). The blocked supernatant was then incubated with a 1 : 1000 dilution of anti-Mdm2 or antiAkt1 antibody at room temperature for 4 h with constant agitation. As a control, an equivalent amount of each lysate was incubated with a nonspecific antibody at the same dilution. Immune complexes were precipitated by the addition of 50 ml of protein A-agarose for 2 h at 41C. After extensive washing, the complexes were resuspended in 50 ml of SDS-PAGE lysing buffer, boiled, and resolved by SDS-12% PAGE. Transfer to PVDF membranes and probing with the 9E10 anti-c-myc epitope monoclonal antibody was as described above.
